Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
March 28 2019 - 7:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq:SGEN) will host a conference call
and webcast discussion regarding the positive topline results from
its pivotal clinical trial of enfortumab vedotin in locally
advanced or metastatic urothelial cancer, which were announced in a
press release earlier today. Access to the event can be obtained as
follows:
LIVE access on Thursday, March 28, 2019
6:00 a.m. Pacific Time (PT) / 9:00 a.m. Eastern Time (ET)
- Telephone 866-288-0540 (domestic) or +1
786-460-7199 (international); conference ID 3807860
- Webcast available at
www.seattlegenetics.com in the Investors section
REPLAY access
- Telephone replay will be available
until 5:00 p.m. PT on Monday, April 1, 2019 by calling 888-203-1112
(domestic) or +1 719-457-0820 (international); conference ID
3807860
- Webcast replay will be available on the
Seattle Genetics website at www.seattlegenetics.com in the
Investors section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European
office in Switzerland. For more information on our robust
pipeline, visit www.seattlegenetics.com and follow
@SeattleGenetics on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190328005178/en/
InvestorsPeggy Pinkston(425)
527-4160ppinkston@seagen.com
MediaMonique Greer(425) 527-4641mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024